RhumbLine Advisers’s ALX Oncology ALXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-46,302
| Closed | -$28.8K | – | 4145 |
|
|
2025
Q1 | $28.8K | Buy |
46,302
+3,786
| +9% | +$2.36K | ﹤0.01% | 3679 |
|
|
2024
Q4 | $71K | Buy |
42,516
+405
| +1% | +$676 | ﹤0.01% | 3578 |
|
|
2024
Q3 | $76.6K | Sell |
42,111
-13,109
| -24% | -$23.9K | ﹤0.01% | 3586 |
|
|
2024
Q2 | $333K | Buy |
55,220
+5,360
| +11% | +$32.3K | ﹤0.01% | 2938 |
|
|
2024
Q1 | $556K | Buy |
49,860
+1,706
| +4% | +$19K | ﹤0.01% | 2608 |
|
|
2023
Q4 | $717K | Sell |
48,154
-2,803
| -6% | -$41.7K | ﹤0.01% | 2458 |
|
|
2023
Q3 | $245K | Buy |
50,957
+607
| +1% | +$2.91K | ﹤0.01% | 3044 |
|
|
2023
Q2 | $378K | Buy |
50,350
+11,443
| +29% | +$85.9K | ﹤0.01% | 2869 |
|
|
2023
Q1 | $176K | Buy |
38,907
+930
| +2% | +$4.21K | ﹤0.01% | 2760 |
|
|
2022
Q4 | $428K | Buy |
37,977
+5,467
| +17% | +$61.6K | ﹤0.01% | 2540 |
|
|
2022
Q3 | $311K | Buy |
32,510
+3,523
| +12% | +$33.7K | ﹤0.01% | 2712 |
|
|
2022
Q2 | $235K | Buy |
28,987
+10,614
| +58% | +$86K | ﹤0.01% | 2865 |
|
|
2022
Q1 | $311K | Buy |
18,373
+1,054
| +6% | +$17.8K | ﹤0.01% | 2632 |
|
|
2021
Q4 | $372K | Sell |
17,319
-302
| -2% | -$6.49K | ﹤0.01% | 2628 |
|
|
2021
Q3 | $1.3M | Buy |
17,621
+1,415
| +9% | +$104K | ﹤0.01% | 2111 |
|
|
2021
Q2 | $886K | Sell |
16,206
-2,069
| -11% | -$113K | ﹤0.01% | 2298 |
|
|
2021
Q1 | $1.35M | Buy |
18,275
+7,311
| +67% | +$539K | ﹤0.01% | 2071 |
|
|
2020
Q4 | $945K | Buy |
10,964
+2,727
| +33% | +$235K | ﹤0.01% | 2157 |
|
|
2020
Q3 | $311K | Buy |
+8,237
| New | +$311K | ﹤0.01% | 2505 |
|